Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 7688 results

  1. Cladribine for treating relapsing multiple sclerosis [ID6263]

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  2. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]

    In development [GID-HST10059] Expected publication date: 05 March 2025

    Highly specialised technologies guidance
    In development

  3. Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults

    In development [GID-IPG10362] Expected publication date: 09 January 2025

    Interventional procedures guidance
    In development

  4. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  5. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  6. Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  8. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  9. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

    Quality standard
    In development

  10. Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre)

    Diagnostics guidance
    Published
    4 July 2018
    View recommendations

    Sections for DG33

  11. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

    Quality standard
    In development

  12. Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

    In development [GID-TA11496] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  13. Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures on radiographic images

    Awaiting development [GID-HTE10059] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  14. Digital platforms to support cardiac rehabilitation

    Awaiting development [GID-HTE10060] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  15. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development [GID-TA11379] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development